Find a Trial
Trial Summary
| Protocol No. | CTO-MK-3475-905 | ||
|---|---|---|---|
| Status | OPEN TO ACCRUAL | ||
| Principal Investigator | Adra, Nabil | ||
| Scope | National | ||
| Phase | Phase III | ||
| Age Group | Adult | ||
| Title | A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfortumab Vedotin and Pembrolizumab versus Cystectomy Alone in Cisplatin-Ineligible Participants with Muscle-Invasive Bladder Cancer (KEYNOTE-905/EV-303) | ||
| Description | A global, randomized phase III study to evaluate perioperative pembrolizumab with radical cystectomy + pelvic lymph node dissection (RC+PLND) versus RC+PLND alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC). | ||
| Key Eligibility | In order to be eligible to take part in this trial, patients must meet the following criteria:
| ||
| Applicable Disease Sites | Urinary Bladder | ||
| Participating Institutions | Indiana University (IU) | ||
| Treatment Type | Treatment | ||
| Contact | Phone: (317) 278-5632 Email: iutrials@iu.edu | ||